MedTrace Logo

Acceptability and Feasibility of Combination Treatment for Cervical Precancer Among South African Women Living With HIV

NCT05413811 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 180

Last updated 2026-02-17

No results posted yet for this study

Summary

The purpose of this study is to explore whether an anti-cancer medication (5-fluorouracil cream) placed in the vagina after a surgical excision procedure is an acceptable and useful form of treatment for cervical precancer among the woman with HIV infection.

Conditions

  • Cervical Cancer
  • CIN2
  • CIN3
  • Human Immunodeficiency Virus
  • Human Papillomavirus

Interventions

DRUG

5 Fluorouracil (5 FU) Cream

Intravaginal topical chemotherapy, 5-fluorouracil cream

DRUG

Placebo

Intravaginal topical placebo cream

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • UNC Lineberger Comprehensive Cancer Center

    lead OTHER

Principal Investigators

  • Carla Chibwesha, MD, MSc · University of North Carolina, Chapel Hill

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-22
Primary Completion
2025-06-30
Completion
2025-06-30

Countries

  • South Africa

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05413811 on ClinicalTrials.gov